Piramal Pharma Limited Converts The Coal-Fired Steamer At Its Digwal Facility To Operate On Biomass Briquettes, Advancing Decarbonization Efforts
Date
1/15/2025 3:01:04 AM
(MENAFN- PR Newswire)
"The transition to
biomass briquettes at our Digwal facility is a testament to our commitment to reducing our environmental footprint while driving innovation in sustainable manufacturing. As we align our goals with global climate action frameworks, we will continue to contribute to a more sustainable future for generations to come," said Nandini Piramal, Chairperson, Piramal Pharma Limited.
Adopting biomass briquettes is a key advancement in Piramal's sustainability journey. These briquettes are compacted blocks of biomass materials processed and compressed under high pressure. Biomass briquettes, made from agricultural waste, are a renewable fuel source that supports circular economy principles by recycling organic by-products, reducing waste, and promoting sustainability.
"This transformation at our
Digwal facility underscores our commitment to environmental stewardship and sustainable operational practices," said Peter DeYoung, Chief Executive Officer of Piramal Global Pharma. "By transitioning to biomass briquettes, we are significantly reducing our GHG emissions and setting new industry standards for responsible pharmaceutical manufacturing."
This initiative supports Piramal's global sustainability goals and demonstrates how pharmaceutical companies can implement effective climate action solutions while maintaining operational excellence. Piramal Pharma Limited remains committed to responsible growth through environmentally friendly practices to support a greener future.
About Piramal Pharma Ltd:
Piramal Pharma Limited (PPL, NSE:PPLPHARMA I BSE:543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market.
For more information, visit: Piramal Pharma
|
LinkedIn
*
Includes one facility via PPL's minority investment in Yapan Bio.
Photo: g
Photo: g
Photo: g
Photo: g
Logo: g
SOURCE Piramal Pharma Ltd
MENAFN15012025003732001241ID1109091873
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.